Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 19 03:48PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-11.09 Insider Own3.02% Shs Outstand1.14M Perf Week-49.84%
Market Cap0.35M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float1.10M Perf Month-80.80%
Income-8.63M PEG- EPS next Q- Inst Own4.19% Short Float2.99% Perf Quarter-81.60%
Sales0.00M P/S- EPS this Y- Inst Trans-34.69% Short Ratio0.47 Perf Half Y-90.16%
Book/sh4.03 P/B0.08 EPS next Y- ROA-89.34% Short Interest0.03M Perf Year-93.60%
Cash/sh3.59 P/C0.09 EPS next 5Y- ROE-113.96% 52W Range0.14 - 8.30 Perf YTD-84.83%
Dividend Est.- P/FCF- EPS past 5Y- ROI-256.90% 52W High-96.25% Beta2.14
Dividend TTM- Quick Ratio2.36 Sales past 5Y0.00% Gross Margin- 52W Low130.37% ATR (14)0.18
Dividend Ex-Date- Current Ratio2.36 EPS Y/Y TTM48.83% Oper. Margin0.00% RSI (14)25.43 Volatility126.85% 41.46%
Employees6 Debt/Eq0.08 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price600.00
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q28.02% Payout- Rel Volume0.11 Prev Close0.24
Sales Surprise- EPS Surprise-50.00% Sales Q/Q- Earnings- Avg Volume69.56K Price0.31
SMA20-63.07% SMA50-77.28% SMA200-88.61% Trades Volume7,872 Change28.51%
Apr-03-24 02:33PM
Mar-25-24 05:00PM
Feb-14-24 05:45PM
Nov-01-23 07:00AM
Oct-31-23 09:00AM
04:30PM Loading…
Oct-05-23 04:30PM
Oct-04-23 07:00AM
Oct-03-23 07:00AM
Sep-26-23 09:15AM
Aug-31-23 06:30AM
May-26-23 04:40PM
Apr-18-23 06:30AM
Jan-17-23 08:20AM
Dec-27-22 05:44PM
Nov-17-22 04:53PM
04:30PM Loading…
Nov-08-22 04:30PM
Oct-14-22 04:01PM
Oct-04-22 08:50AM
Jul-24-22 08:41AM
Jun-02-22 04:30PM
May-17-22 11:34AM
May-16-22 04:10PM
Apr-27-22 04:45PM
Apr-20-22 05:49PM
Ampio Pharmaceuticals, Inc. operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease. The company was founded by David Bar-Or in December 2008 and is headquartered in Englewood, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BUCHI J KEVINDirectorJun 09 '23Buy0.2921,8586,284146,858Jun 13 12:07 PM
BUCHI J KEVINDirectorJun 08 '23Buy0.3025,0007,400125,000Jun 09 02:26 PM
MARTINO MICHAEL ACEOMay 24 '23Buy0.2976,89022,12176,890May 26 01:30 PM
BUCHI J KEVINDirectorMay 16 '23Buy0.2732,5348,924100,000May 17 04:25 PM
BUCHI J KEVINDirectorMay 15 '23Buy0.2544,02610,85767,466May 16 03:30 PM
Stevens David RDirectorMay 12 '23Buy0.2245,0009,900103,971May 12 05:26 PM
BUCHI J KEVINDirectorMay 12 '23Buy0.2423,4405,51323,440May 16 03:30 PM
Stevens David RDirectorMay 11 '23Buy0.2250,00010,87558,971May 12 05:26 PM